Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):221-8. doi: 10.1176/appi.ajp.2007.07010089. Epub 2008 Jan 2.

PMID:
18172017
2.

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR.

Biol Psychiatry. 2004 Sep 1;56(5):301-7. Review.

PMID:
15336511
3.

[Schizophrenia Cognition Rating Scale Japanese version (SCoRS-J) as a co-primary measure assessing cognitive function in schizophrenia].

Kaneda Y, Ueoka Y, Sumiyoshi T, Yasui-Furukori N, Ito T, Higuchi Y, Suzuki M, Ohmori T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Nov;31(5-6):259-62. Review. Japanese.

PMID:
22256616
4.

[Functional outcome in schizophrenia: relation to the MATRICS consensus cognitive battery].

Sumiyoshi C.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Nov;31(5-6):251-7. Review. Japanese.

PMID:
22256615
5.

Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.

Keefe RS, Harvey PD.

Schizophr Bull. 2008 Jul;34(4):656-63. doi: 10.1093/schbul/sbn042. Epub 2008 May 20. Review.

6.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
7.

[Measuring the cognitive deficit associated with schizophrenia: presentation of the MATRICS neuropsychological test battery].

Sarolta K, Pál C, István B.

Neuropsychopharmacol Hung. 2007 Oct;9(3):143-50. Review. Hungarian. Erratum in: Neuropsychopharmacol Hung. 2007 Dec;9(4):207.

8.

Stimulating the development of drug treatments to improve cognition in schizophrenia.

Green MF.

Annu Rev Clin Psychol. 2007;3:159-80. Review.

PMID:
17716052
9.

[Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].

Rodríguez-Jiménez R, Bagney A, Moreno-Ortega M, García-Navarro C, Aparicio AI, López-Antón R, de la Oliva J, Jiménez-Arriero MÁ, Santos JL, Lobo A, Palomo T.

Rev Neurol. 2012 Nov 1;55(9):549-55. Review. Spanish.

10.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
11.

Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB.

Levaux MN, Potvin S, Sepehry AA, Sablier J, Mendrek A, Stip E.

Eur Psychiatry. 2007 Mar;22(2):104-15. Epub 2007 Jan 16. Review.

PMID:
17227707
12.

Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change.

Silverstein SM.

Schizophr Bull. 2008 Jul;34(4):645-55. doi: 10.1093/schbul/sbn032. Epub 2008 May 8. Review.

13.
14.
15.
16.

The NIMH-MATRICS consensus statement on negative symptoms.

Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR.

Schizophr Bull. 2006 Apr;32(2):214-9. Epub 2006 Feb 15. No abstract available.

17.

The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC).

Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, Burdick KE, Martínez-Arán A, Dittmann S, Goldberg JF, Ozerdem A, Aydemir O, Chengappa KN.

Bipolar Disord. 2010 Jun;12(4):351-63. doi: 10.1111/j.1399-5618.2010.00830.x. Review.

PMID:
20636632
18.

A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.

Ruchlin HS, Insinga RP.

Pharmacoeconomics. 2008;26(11):925-35. Review.

PMID:
18850762
19.

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA.

Pharmacol Ther. 2009 May;122(2):150-202. doi: 10.1016/j.pharmthera.2009.02.004. Epub 2009 Mar 6. Review.

20.

Cognitive performance and basic symptoms in first-degree relatives of schizophrenic patients.

Bove EA.

Compr Psychiatry. 2008 Jul-Aug;49(4):321-9. doi: 10.1016/j.comppsych.2008.01.001. Epub 2008 Mar 20. Review.

PMID:
18555050
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk